These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 9820296

  • 21. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S, Rahimi R, Abdollahi M.
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [Abstract] [Full Text] [Related]

  • 22. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T, Tashiro K, Itoyama Y, Sato T, Ohashi Y, Zhao Z, Interferon Beta-1b Multiple Sclerosis Study Group of Japan.
    Neurology; 2005 Feb 22; 64(4):621-30. PubMed ID: 15728282
    [Abstract] [Full Text] [Related]

  • 23. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr 22; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.
    Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C.
    Mult Scler; 1995 Apr 22; 1 Suppl 1():S51-4. PubMed ID: 9345400
    [Abstract] [Full Text] [Related]

  • 28. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS.
    Kappos L, Polman C, Pozzilli C, Thompson A, Beckmann K, Dahlke F, European Study Group in Interferon beta-1b in Secondary-Progressive MS.
    Neurology; 2001 Dec 11; 57(11):1969-75. PubMed ID: 11739811
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O, Wergeland S, Bakke S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Lilleås F, Pedersen T, Bjørnarå B, Dalene F, Kleveland G, Schepel J, Olsen IC, Myhr KM.
    Arch Neurol; 2012 Aug 11; 69(8):1044-51. PubMed ID: 22507886
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
    Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
    [Abstract] [Full Text] [Related]

  • 33. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 24; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
    Lancet Neurol; 2011 Apr 24; 10(4):338-48. PubMed ID: 21397567
    [Abstract] [Full Text] [Related]

  • 36. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 24; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.
    Clin Ther; 2008 Jun 24; 30(6):1102-12. PubMed ID: 18640466
    [Abstract] [Full Text] [Related]

  • 40. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr 24; 43(4):655-61. PubMed ID: 8469318
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.